Paul HUDSON

About Paul HUDSON

Paul Hudson is a British healthcare executive best known for serving as Chief Executive Officer of Sanofi from September 2019 to February 2026. Sanofi also stated that his director mandate ended on February 18, 2026. His tenure is closely associated with the company’s transformation toward a more innovation-led, science-driven, and patient-access-oriented biopharma model. During his leadership, Sanofi placed greater emphasis on strengthening research and development, accelerating priorities in immunology, rare diseases, vaccines, and specialty care, and modernizing the group’s management culture. Before joining Sanofi, Hudson was Chief Executive Officer of Novartis Pharmaceuticals from 2016 to 2019. His international career in healthcare was built through increasingly senior roles across Europe, the United States, and Japan. At AstraZeneca, he held several leadership positions, including President of AstraZeneca US and Executive Vice President, North America. He began his career in sales and marketing at GlaxoSmithKline UK and Sanofi-Synthélabo UK, which gave him a strong grounding in commercial execution, market access, portfolio management, and brand building. This background has made him widely recognized for strategic leadership, large-scale transformation, and the management of complex global organizations. As Sanofi’s CEO, Hudson supported a major modernization of the company’s identity and helped reposition the group as a leading biopharma player with a stronger scientific focus. He also backed a broader social-impact agenda, including initiatives related to corporate responsibility and access to medicines. His leadership style emphasized long-term performance, execution discipline, and the creation of sustainable value through more focused scientific investment. A graduate in economics from Manchester Metropolitan University, he was awarded an honorary Doctor of Business Administration in 2018 for his achievements in industry.